The U.S. Food and Drug Administration approved Omeros Corp.’s Yartemlea (narsoplimab) as the first treatment for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA), a life‑threatening complication of hematopoietic stem cell transplantation. The approval provides clinicians with a targeted option for a condition that previously lacked an approved therapy. TA‑TMA is a microvascular injury syndrome that can follow stem cell transplant and carries high morbidity and mortality; approval follows clinical data showing benefit in affected patients. Omeros now holds the first labeled therapy for this indication, which could shift standards of care in transplant centers and influence hospital formularies.